Vizsgálati helyszín
Vital-Medicina Kft.
Veszprem, 8200, MagyarországEU-13 felzárkózó országMég nincs intézményhez kötve
- 20futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 35 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis21 vizsgálat
- 2. fázis10 vizsgálat
- 4. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz15 vizsgálat
- Lezárult13 vizsgálat
- Toboroz4 vizsgálat
- Még nem toboroz1 vizsgálat
- Felfüggesztve1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC7 vizsgálat
- AbbVie6 vizsgálat
- Novartis Pharmaceuticals4 vizsgálat
- MoonLake Immunotherapeutics AG3 vizsgálat
- Eli Lilly and Company2 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
2025-522076-85-00· 2. fázis· AstraZeneca AB· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
International study to compare the efficacy and safety of chondroitin sulfate 800 mg tablets of two different origins (bovine versus marine) in the treatment of knee osteoarthritis
2024-516337-12-00· 3. fázis· IBSA Institut Biochimique SA· Forrás
Fut, nem toboroz
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis
2024-519291-11-00· 2. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· 2. fázis· Immunovant Sciences GmbH· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)
2022-500700-22-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Fut, nem toboroz
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
2024-510826-16-00· 3. fázis· Mabxience Research S.L.· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
NCT06028438· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448· 2. fázis· Lakefront Biotherapeutics NV· Forrás
Lezárult
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627· 3. fázis· AbbVie· Forrás
Lezárult
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
NCT05848258· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is
2022-501362-22-00· 2/3. fázis· Acelyrin Inc.· Forrás
Lezárult
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis
2022-501425-20-00· 2. fázis· Eli Lilly & Co.· Forrás
Lezárult
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
NCT05767034· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
NCT04886258· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· 4. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
NCT04169373· 3. fázis· AbbVie· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· 4. fázis· Eli Lilly and Company· Forrás
Hibát jelzek